John Leonard, Intellia Therapeutics CEO
Intellia gets FDA clearance to start hereditary angioedema gene editing trial in US
Intellia Therapeutics announced Thursday morning that the FDA cleared it to test a gene editing therapy for hereditary angioedema (HAE) in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
